Skip to main navigation Skip to search Skip to main content

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma

  • Yonggang Wang
  • , Chang Wang
  • , Yanqiao Zhang
  • , Jiqing Hao
  • , Nong Yang
  • , Jvfeng Wang
  • , Min Peng
  • , Tianshu Liu
  • , Guifang Zhang
  • , Xianbao Zhan
  • , Shan Zeng
  • , Yifan Zhang
  • , Yong Gao*
  • , Yang Yao*
  • *Corresponding author for this work
  • Shanghai Jiao Tong Univ
  • First Hosp Jilin Univ
  • Harbin Med Univ
  • Anhui Med Univ
  • Hunan Canc Hosp
  • Zhengzhou Univ
  • Fudan Univ
  • Xinxiang Cent Hosp
  • Second Mil Med Univ
  • Cent South Univ
  • Chinese Acad Sci
  • Tongji Univ

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background and purposeThe objective of this study was to investigate the pharmacokinetics, safety, and antitumor activity of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and evaluate the effect of dose titration on dosage optimization for individual patients. MethodsPatient with advanced gastric adenocarcinoma progressed after at least one line of chemotherapy were enrolled. Apatinib was given orally once daily starting at 500 mg for 14 days, then up-titrated to 750 mg for 14 days, and then proceeded to a maximum dose of 850 mg. Dose up-titration determination was based on toxicity. The 28-day treatment cycles continued until disease progression, intolerable toxicities, withdrawal of consent, or investigator' decision. ResultsA total of 60 patients were enrolled, with 17, 18, and 25 patients receiving a maximum dose of 500 mg, 750 mg, and 850 mg, respectively. The pharmacokinetic parameters varied considerably, with the interpatient coefficient of variation for steady state areas under the plasma concentration time curve (AUC(ss)) and the mean maximum concentration of both > 50%. During 500 mg and 750 mg dosing stage, drug exposures in patients with a maximum dosage of 850 mg were lower than in those not titrated to 850 mg. Patients with total gastrectomy exhibited significantly lower AUC(ss) than patients with partial or no gastrectomy (p = 0.004 and 0.032, respectively). Toxicities were tolerable, and disease control rate was 39.5% (95% CI 25.0%-55.6%). ConclusionsApatinib dose titration based on toxicity could be used in clinical practice to provide optimal dosage for individual patients.
Original languageEnglish
Article number876899
Number of pages10
JournalFRONTIERS IN ONCOLOGY
Volume12
DOIs
StatePublished - 18 Oct 2022

Keywords

  • apatinib
  • angiogenesis
  • gastric adenocarcinoma
  • pharmacokinetics
  • VEGFR
  • VEGFR-2

Indexed by

  • SCIE
  • Scopus

Fingerprint

Dive into the research topics of 'Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma'. Together they form a unique fingerprint.

Cite this